Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.01 – $8.90
0% from low
Exchange
OTC Link
CS
CERO TERAPEUTICS HLDG INC
No one on the platform currently holds CERO.
No tracked institution reports a position in CERO as of their last filing.
| Execution date | Ratio |
|---|---|
| 2025-06-13 | 1-for-20reverse |
| 2025-01-08 | 1-for-100reverse |
No one on the platform has traded CERO yet.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $0 | — | $-2.50 | $-2.50–$-2.50 | — | 1 |
| 2027 | $0 | — | $-3.26 | $-3.26–$-3.26 | — | 1 |
| 2028 | $0 | — | $-2.76 | $-2.76–$-2.76 | — | 1 |
| 2029 | $52M | — | $-2.80 | $-2.80–$-2.80 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 5 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-05-15 | $-0.80 | $-0.20 | +75.0% |
| 2026-02-25 | $-0.75 | $-0.75 | +0.0% |
| 2025-11-19 | $-0.76 | $-9.10 | -1097.4% |
| 2025-08-22 | $-124.26 | $-61.71 | +50.3% |
| 2025-05-15 | $-5.96 | $-1.59 | +73.3% |
| $4M |
| — |
| LIMNLiminatus Pharma, Inc. Class A Common Stock | $0.15 | +38.16% | $10M | — |
| MLECMoolec Science S.A. | $6.99 | -4.25% | $5M | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$CERO Shareholders should fire the management and sell it for another company, otherwise this will be a burning money hole for years ...
View on StockTwits ↗$CERO we are due for an update. hopefully buy the end of today but by the end of august will do as long as its explosive!
View on StockTwits ↗$ACON I still own and did not expect $CERO to be De-listed last year for allowing shareholder equity to drop below $2.5 million and their numerous Reverse Splits. But, bam about $2 to less than $.10 in a day. Knowing J. Thramann and his friends that are running this company, I think the plan was always to sell the company (as Thramann has done before). Never to really have a viable revenue generating company. Remember, they just recently turned down a $4 cash offer to buy it.
View on StockTwits ↗$CERO So before delisting they had supposed funding. They were going to present to Nasdaq. They are a one trick pony. They have one: go / no go study. Why would the funding entity wish them to be on Nasdaq? With all the trading and shorting there is no advantage, especially if behind the scenes there is an investor in the wings. They would simply wait it out for the data on the trials. This seems to be happening with more frequency. Anyone else seeing this trend?
View on StockTwits ↗$CERO lol why are we bearish? Been bag holding for a min🥸
View on StockTwits ↗$CERO havnt lost hope on this , we will be back 🙏
View on StockTwits ↗$CERO All they had to do is get the fundings to stay de-listed, now this turned to nothing. Even re-listing will mean reverse split. Only option for shareholders to get some value is a buyout and full de-listing
View on StockTwits ↗$CRDF @jrh34 you forgot $CERO in your example! they had insiders buying plus countless other companies I do not case one way or another but all I am trying to say you cant bundle a whole lot of companies into a salat bowl and make a legit conclusion based on that salad, a decision MUST be exclusively based on that company's merit. Saying "xyz" will be the next "123" is fine in order to give readers an idea of the trajectory, but saying "xyz" will succeed or fail because "123" succeeded or failed is nonsense
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.